Diligence memo · auto-generated · as of July 2, 2026
Synvitrobio, Inc.
Synvitrobio, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Synvitrobio, Inc. operates in Other Health Care, based in SAN LEANDRO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Synvitrobio, Inc. has raised $18M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2023-09-08.
Most recent recorded round closed around 2023-09-08.
Valuation (modeled)modeled
Provath models Synvitrobio, Inc. at approximately $147M (range $41M–$308M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.97× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (97% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 82% of Other Health Care peers (5377 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.